SecBot SecBot
8-K ·Filed Aug 17, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed3mo ago SEC0001140361-26-033282
8-K material event: Items 1.01
Actionable Insight • Neutral

The removal of a large KKR overhang is a modest positive for the stock, but the secondary itself is a neutral event for BridgeBio's fundamentals. Monitor for any subsequent insider selling or changes in institutional ownership post-offering.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$79.89
T+0 close · Aug 17, 2026 · via day close
Latest settled
−2.45%
T+60 · $77.93
Vs SPY
+0.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $79.89entry
  2. T+1 · 3mo ago +3.87%α +4.54% · $82.98
  3. T+5 · 3mo ago +1.48%α +2.67% · $81.07
  4. T+20 · 2mo ago −9.40%α −7.87% · $72.38
  5. T+60 · 6d ago −2.45%α +0.31% · $77.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share in an underwritten secondary offering. BridgeBio receives no proceeds, but the transaction diversifies its shareholder base and removes a large overhang from a major institutional holder. The offering is expected to close on August 17, 2026, with a 30-day lock-up on the selling stockholder.

Key Facts

  • KKR Genetic Disorder L.P. is selling 5,000,000 shares of BBIO common stock at $78.00 per share.
  • BridgeBio will not receive any proceeds from the offering.
  • The offering is oversubscribed and priced at $78.00 per share, with underwriters paying $77.415 per share.
  • Underwriters include William Blair, Goldman Sachs, and KKR Capital Markets.
  • The selling stockholder is subject to a 30-day lock-up agreement.
  • The offering is expected to close on August 17, 2026.

Financial Impact

Secondary offering of 5,000,000 shares at $78.00 per share; gross proceeds of $390 million to the selling stockholder. BridgeBio receives $0.

dilutionshareholder base composition

Risk Factors

  • No direct financial benefit to BridgeBio from the offering.
  • Potential for further selling by other large holders if the lock-up expiration leads to distribution.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-033282
Document: ef20080234_8k.htm0001140361-26-033282
Document: ef20080234_ex99-2.htm0001140361-26-033282
Document: ef20080234_ex5-1.htm0001140361-26-033282
Document: ef20080234_ex99-1.htm0001140361-26-033282
Document: 0001140361-26-033282-index-headers.html0001140361-26-033282
Document: 0001140361-26-033282-index.html0001140361-26-033282
Document: 0001140361-26-033282.txt0001140361-26-033282

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026